A novel technique for selective NF-kappaB inhibition in Kupffer cells: contrary effects in fulminant hepatitis and ischaemia-reperfusion
Related Experiment Video
Updated: May 12, 2026
Use of a Hanging-weight System for Liver Ischemia in Mice
Published on: August 7, 2012
F Hoffmann1, G Sass, J Zillies
1Department of Pharmacy, Center of Drug Research, Butenandtstrasse 5-13, D-81377 Munich, Germany.
Background And Aims:
The transcription factor nuclear factor kappa B (NF-kappaB) has risen as a promising target for anti-inflammatory therapeutics. In the liver, however, NF-kappaB inhibition mediates both damaging and protective effects. The outcome is deemed to depend on the liver cell type addressed. Recent gene knock-out studies focused on the role of NF-kappaB in hepatocytes, whereas the role of NF-kappaB in Kupffer cells has not yet been investigated in vivo. Here we present a novel approach, which may be suitable for clinical application, to selectively target NF-kappaB in Kupffer cells and analyse the effects in experimental models of liver injury.
Methods:
NF-kappaB inhibiting decoy oligodeoxynucleotides were loaded upon gelatin nanoparticles (D-NPs) and their in vivo distribution was determined by confocal microscopy. Liver damage, NF-kappaB activity, cytokine levels and apoptotic protein expression were evaluated after lipopolysaccharide (LPS), d-galactosamine (GalN)/LPS, or concanavalin A (ConA) challenge and partial warm ischaemia and subsequent reperfusion, respectively.
Results:
D-NPs were selectively taken up by Kupffer cells and inhibited NF-kappaB activation. Inhibition of NF-kappaB in Kupffer cells improved survival and reduced liver injury after GalN/LPS as well as after ConA challenge. While anti-apoptotic protein expression in liver tissue was not reduced, pro-apoptotic players such as cJun N-terminal kinase (JNK) were inhibited. In contrast, selective inhibition of NF-kappaB augmented reperfusion injury.
Conclusions:
NF-kappaB inhibiting decoy oligodeoxynucleotide-loaded gelatin nanoparticles is a novel tool to selectively inhibit NF-kappaB activation in Kupffer cells in vivo. Thus, liver injury can be reduced in experimental fulminant hepatitis, but increased at ischaemia-reperfusion.
Insights
Selective inhibition of nuclear factor kappa B (NF-kappaB) in Kupffer cells using novel nanoparticles reduced liver injury in models of hepatitis. However, this approach worsened injury in ischemia-reperfusion scenarios, highlighting cell-specific effects.
Area of Science:
- Immunology
- Hepatology
- Nanomedicine
Background:
- Nuclear factor kappa B (NF-kappaB) is a key regulator of inflammation with dual roles in liver injury.
- Previous studies focused on NF-kappaB in hepatocytes, leaving its role in Kupffer cells unexplored in vivo.
- Targeting NF-kappaB selectively in Kupffer cells offers a potential therapeutic strategy for liver diseases.
Purpose of the Study:
- To develop and evaluate a novel nanoparticle-based system for selective NF-kappaB inhibition in Kupffer cells.
- To analyze the effects of this targeted inhibition on experimental models of liver injury.
- To investigate the cell-type-specific consequences of NF-kappaB inhibition in the liver.
Main Methods:
- NF-kappaB-inhibiting decoy oligodeoxynucleotides were encapsulated in gelatin nanoparticles (D-NPs).
- In vivo distribution of D-NPs was visualized using confocal microscopy.
- Liver injury, NF-kappaB activity, cytokine levels, and apoptosis were assessed in various liver injury models (LPS, GalN/LPS, ConA, ischemia-reperfusion).
Main Results:
- D-NPs were selectively taken up by Kupffer cells, effectively inhibiting NF-kappaB activation.
- Targeted NF-kappaB inhibition in Kupffer cells improved survival and reduced liver damage in fulminant hepatitis models (GalN/LPS, ConA).
- While anti-apoptotic protein expression remained unchanged, pro-apoptotic JNK was inhibited; however, ischemia-reperfusion injury was exacerbated.
Conclusions:
- Gelatin nanoparticle-loaded decoy oligodeoxynucleotides provide a novel method for selective in vivo NF-kappaB inhibition in Kupffer cells.
- This targeted approach mitigates liver injury in experimental fulminant hepatitis.
- Conversely, selective NF-kappaB inhibition in Kupffer cells exacerbates ischemia-reperfusion injury, underscoring context-dependent effects.
Related Concept Videos
02:26NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
01:30Inhibitors of Viral Protein Synthesis